{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-011152","form_type":"8-K","ticker":"SCNX","cik":"0001382574","company_name":"Scienture Holdings, Inc.","filed_at":"2025-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.485484+00:00","generated_at":"2026-05-24T08:36:58.563936+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Scienture receives FDA approval for Arbli (losartan oral suspension); launch planned Q3 2025","bullets":["FDA approves SCN-102 as Arbli (losartan potassium oral suspension), first liquid ready-to-use losartan in US.","Arbli indicated for hypertension (age >6), stroke risk reduction, diabetic nephropathy.","US losartan market $292M annual sales, 68M prescriptions (IQVIA Dec 2024); global $1.5B.","Commercial launch expected Q3 2025; product has 18-month shelf life at room temp.","Consulting agreement with Draper Inc. for IR/business dev: 100k shares initial + 100k/mo."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-011152","json":"https://secwatch.observer/filing/0001493152-25-011152.json","markdown":"https://secwatch.observer/filing/0001493152-25-011152.md","text":"https://secwatch.observer/filing/0001493152-25-011152.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382574/000149315225011152/0001493152-25-011152-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382574/000149315225011152/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T08:36:58.563936+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}